<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">3863</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">5</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2018</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">18</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.ki67<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div><div class='content chap10-para'>Ki-67 (MIB-1) (Proliferative Index) is a marker of cell proliferation. A high value indicates a tumor that is proliferating more rapidly. Codes and coding instructions for this data item are site-specific.</div><div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div><div class='content chap10-para'>Ki-67 (MIB-1) (Proliferative Index) is a Registry Data Collection Variable in AJCC. It was a new data item for breast cases diagnosed 1/1/2018+. It will apply to neuroendocrine tumors (NET) of the gastrointestinal tract (AJCC Chapters 29 &#8211; 34) for cases diagnosed 1/1/2021+. High Ki-67 is an adverse prognostic factor and Ki-67 is a component of grade for these tumors. NCCN guidelines recommend that tumor differentiation, mitotic rate and Ki-67 should be recorded in the pathology report for these tumors.</div><div class='content chap10-para'><strong>Codes</strong></div><div class='content chap10-para'><table><tr class='code-row'><td class='code-nbr'>0.0-100.0</td><td class='code-desc'>0.0 to 100.0 percent positive: enter percent positive </td></tr><tr class='code-row'><td class='code-nbr'>XXX.4</td><td class='code-desc'>Ki-67 stated as less than 3% </td></tr><tr class='code-row'><td class='code-nbr'>XXX.5</td><td class='code-desc'>Ki-67 stated as 3%-20%</td></tr><tr class='code-row'><td class='code-nbr'>XXX.6</td><td class='code-desc'>Ki-67 stated as greater than 20%</td></tr><tr class='code-row'><td class='code-nbr'>XXX.7</td><td class='code-desc'>Test done, actual percentage not stated</td></tr><tr class='code-row'><td class='code-nbr'>XXX.8</td><td class='code-desc'>Not applicable: Information not collected for this case<br/>
(If this item is required by your standard setter, use of code XXX.8 will result in an edit error.)
</td></tr><tr class='code-row'><td class='code-nbr'>XXX.9</td><td class='code-desc'>Not documented in medical record<br/>
Ki-67 (MIB-1) not assessed or unknown if assessed
</td></tr><tr class='code-row'><td class='code-nbr' colspan='2'></td></tr></table></div><div class='content chap10-para'>Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.</div>